KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-Current Debt: 2011-2021

Historic Non-Current Debt for Supernus Pharmaceuticals (SUPN) over the last 1 years, with Dec 2021 value amounting to $379.3 million.

  • Supernus Pharmaceuticals' Non-Current Debt was N/A to $379.3 million in Q4 2021 from the same period last year, while for Dec 2021 it was $379.3 million, marking a year-over-year change of. This contributed to the annual value of $379.3 million for FY2021, which is N/A change from last year.
  • According to the latest figures from Q4 2021, Supernus Pharmaceuticals' Non-Current Debt is $379.3 million, which was up 4,655.51% from $8.0 million recorded in Q1 2013.
  • In the past 5 years, Supernus Pharmaceuticals' Non-Current Debt ranged from a high of $379.3 million in Q4 2021 and a low of $379.3 million during Q4 2021.
  • For the 1-year period, Supernus Pharmaceuticals' Non-Current Debt averaged around $379.3 million, with its median value being $379.3 million (2021).